mojo

"A GLP-1 medication tracker app for iOS and Android that connects health data and provides real-time AI feedback, change detection, and personalized insights."
0
mojoapp.ai
Maker: hanamizuki
$1,150/mo with 200 paying users and 4,000 downloads

Marketing Channels

Primary

App Store / Google Play

Available on iOS/Android with 4,000 downloads, suggesting app store discovery is a key channel

Secondary

Hacker News

Shared on HN project showcase thread

Growth Levers

  • Target GLP-1 communities on Reddit, Facebook groups, and TikTok where medication users share experiences
  • Add Apple Health and Health Connect deep integrations to become the default tracking companion
  • Partner with GLP-1 telehealth providers (Ro, Hims, Calibrate) for co-marketing or referral deals
  • Create content around GLP-1 health outcomes and progress stories to drive organic search traffic
  • Implement referral rewards for existing users to share with others on the same medication journey

First Customer Strategy

The creator built a mobile app targeting the rapidly growing GLP-1 medication user base, leveraging app store distribution to reach 4,000 downloads with a 5% conversion rate to 200 paying users.

Pricing Insight

At $1,150/mo from 200 paying users, the average revenue per user is approximately $5.75/mo, suggesting a low-price subscription model accessible to the broad GLP-1 user community. The 5% free-to-paid conversion rate (200/4000) is solid for a health app.

Key Takeaways

  • • Riding a macro health trend (GLP-1 adoption) provides strong tailwinds for niche app growth
  • • A 5% free-to-paid conversion rate with a health-focused app demonstrates genuine value delivery
  • • Connecting to existing health platforms (Apple Health, Health Connect) reduces user friction and increases retention
  • • AI-powered proactive insights differentiate from simple manual logging apps
  • • Mobile-first distribution via app stores provides built-in discoverability for health and fitness categories

Sentiment Analysis

Comments

0 total

No comments yet.